|View printer-friendly version|
|Gilead Sciences Announces CEO John F. Milligan to Step Down|
-- Dr. Milligan to Remain With Company Through Year End --
“It has been an honor to work at Gilead for my entire professional career and, now that the company is on solid footing for the future, the Board and I have agreed it is a good time to turn the reins over to a new leader,” said Dr. Milligan. “I’m looking forward to a well-deserved break and will then move on to new and different opportunities.”
“Today, Gilead has the right strategy in place to successfully execute
on its mission of improving the lives of people with some of the world’s
most serious diseases, led by a robust HIV franchise, an
industry-leading cell therapy platform and a late-stage pipeline in NASH
and inflammation,” commented
“On behalf of the entire Board, I want to thank
Dr. Milligan will also step down from the Gilead Board of Directors at the end of the year. Additionally, Dr. Martin has announced his intent to step down from the Board at the time a new CEO joins the company, having determined that this would be a natural transition point from his successive roles as CEO, Executive Chairman and Chairman.
The Company today also released its financial results for the second
quarter 2018. As previously announced, at
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended
Gilead Sciences, Inc.
Minimum 20 minute delay